LT3149019T - Cholano dariniai, skirti naudoti fxr ir tgr5/gpbar1 medijuojamų ligų gydymui ir (arba) prevencijai - Google Patents

Cholano dariniai, skirti naudoti fxr ir tgr5/gpbar1 medijuojamų ligų gydymui ir (arba) prevencijai

Info

Publication number: LT3149019T
Authority: LT; Lithuania
Prior art keywords: tgr5; fxr; prevention; treatment; mediated diseases
Prior art date: 2014-05-29

Application number

LTEP15731260.4T

Other languages

English (en)

Inventor

Angela ZAMPELLA

Stefano Fiorucci

Original Assignee

Bar Pharmaceuticals S.R.L.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-05-29

Filing date

2015-05-28

Publication date

2020-02-25

2015-05-28 Application filed by Bar Pharmaceuticals S.R.L. filed Critical Bar Pharmaceuticals S.R.L.

2020-02-25 Publication of LT3149019T publication Critical patent/LT3149019T/lt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Virology (AREA)
Toxicology (AREA)
Obesity (AREA)
Hematology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Tropical Medicine & Parasitology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
AIDS & HIV (AREA)
Biotechnology (AREA)

LTEP15731260.4T 2014-05-29 2015-05-28 Cholano dariniai, skirti naudoti fxr ir tgr5/gpbar1 medijuojamų ligų gydymui ir (arba) prevencijai LT3149019T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ITFI20140130		2014-05-29
PCT/EP2015/061802 WO2015181275A1 (en)	2014-05-29	2015-05-28	Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases

Publications (1)

Publication Number	Publication Date
LT3149019T true LT3149019T (lt)	2020-02-25

Family

ID=51454763

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP19204247.1T LT3626725T (lt)	2014-05-29	2015-05-28	Cholano dariniai skirti naudoti ligų, kurių atsiradimui tarpininkauja fxr ir tgr5/gpbar1, gydymui ir (arba) profilaktikai
LTEP15731260.4T LT3149019T (lt)	2014-05-29	2015-05-28	Cholano dariniai, skirti naudoti fxr ir tgr5/gpbar1 medijuojamų ligų gydymui ir (arba) prevencijai

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP19204247.1T LT3626725T (lt)	2014-05-29	2015-05-28	Cholano dariniai skirti naudoti ligų, kurių atsiradimui tarpininkauja fxr ir tgr5/gpbar1, gydymui ir (arba) profilaktikai

Country Status (25)

Country	Link
US (2)	US10407462B2 (lt)
EP (2)	EP3626725B1 (lt)
JP (1)	JP6820253B2 (lt)
KR (1)	KR102491556B1 (lt)
CN (2)	CN106661079B (lt)
AU (1)	AU2015265893B2 (lt)
CA (1)	CA2948585C (lt)
CY (1)	CY1122631T1 (lt)
DK (2)	DK3149019T3 (lt)
EA (1)	EA032820B1 (lt)
ES (2)	ES2768718T3 (lt)
FI (1)	FI3626725T3 (lt)
HR (2)	HRP20200225T1 (lt)
HU (2)	HUE061506T2 (lt)
LT (2)	LT3626725T (lt)
MA (1)	MA39881B1 (lt)
MX (2)	MX373721B (lt)
PH (1)	PH12016502327A1 (lt)
PL (2)	PL3149019T3 (lt)
PT (2)	PT3626725T (lt)
RS (2)	RS64050B1 (lt)
SG (2)	SG11201609403UA (lt)
SI (2)	SI3626725T1 (lt)
SM (2)	SMT202300057T1 (lt)
WO (1)	WO2015181275A1 (lt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2545964A1 (en)	2011-07-13	2013-01-16	Phenex Pharmaceuticals AG	Novel FXR (NR1H4) binding and activity modulating compounds
WO2015181275A1 (en) *	2014-05-29	2015-12-03	Bar Pharmaceuticals S.R.L.	Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases
WO2016045480A1 (zh) *	2014-09-28	2016-03-31	上海源力生物技术有限公司	一种奥贝胆酸的制备方法
BR112017009657A2 (pt)	2014-11-06	2018-01-23	Enanta Pharmaceuticals, Inc	análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
CN105669811B (zh) *	2014-11-17	2020-09-04	正大天晴药业集团股份有限公司	新的7-酮-6β-烷基胆烷酸衍生物在制备奥贝胆酸以及其在医药领域的用途
WO2016079520A1 (en)	2014-11-19	2016-05-26	Dextra Laboratories Limited	6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
KR102526631B1 (ko)	2014-11-19	2023-04-27	엔제트피 유케이 리미티드	스테로이드 fxr 조절인자를 제조하기 위한 중간체로서의 6-알킬-7-하이드록시-4-엔-3-온 스테로이드
MX375864B (es)	2014-11-19	2025-03-07	Nzp Uk Ltd	Esteroides de 5.beta-6-alquil-7-hidroxi-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr)
CN107108688B (zh)	2014-11-19	2019-10-29	Nzp英国有限公司	作为制备类固醇FXR调节剂的中间体的6α-烷基-3,7-二酮类固醇
WO2016086115A1 (en)	2014-11-26	2016-06-02	Enanta Pharmaceuticals, Inc.	Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
US10208081B2 (en)	2014-11-26	2019-02-19	Enanta Pharmaceuticals, Inc.	Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
CA2968404A1 (en)	2014-11-26	2016-06-02	Enanta Pharmaceuticals, Inc.	Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
RU2017130466A (ru)	2015-02-11	2019-03-12	Энанта Фармасьютикалс, Инк.	Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения
SI3277286T1 (sl)	2015-03-31	2021-09-30	Enanta Pharmaceuticals, Inc.	Derivati žolčne kisline kot antagonisti FXR/TGR5 in metode za njihovo uporabo
US10800807B2 (en) *	2015-06-19	2020-10-13	Intercept Pharmaceuticals, Inc.	TGR5 modulators and methods of use thereof
HK1254057A1 (zh) *	2015-09-24	2019-07-12	英特塞普特医药品公司	用於制备胆汁酸衍生物的方法和中间体
WO2017147137A1 (en)	2016-02-23	2017-08-31	Enanta Pharmaceuticals, Inc.	Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
US10323061B2 (en)	2016-02-23	2019-06-18	Enanta Pharmaceuticals, Inc.	Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
US10364267B2 (en)	2016-02-23	2019-07-30	Enanta Pharmaceuticals, Inc.	Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
PT3426348T (pt) *	2016-03-11	2021-06-28	Intercept Pharmaceuticals Inc	Derivado de 3-desoxi e composições farmacêuticas do mesmo
CN105859817A (zh) *	2016-05-09	2016-08-17	成都宇西医药技术有限公司	一种制备3α-羟基-6-乙烯基-7-酮基-5β-胆烷酸的方法
GB201608777D0 (en)	2016-05-18	2016-06-29	Dextra Lab Ltd	Compounds
WO2017207648A1 (en)	2016-05-31	2017-12-07	Bionice, S.L.U	Process and intermediates for the preparation of obeticholic acid and derivatives thereof
WO2017208165A1 (en) *	2016-06-01	2017-12-07	Dr. Reddy’S Laboratories Limited	Process for preparation of obeticholic acid
CA2968836C (en)	2016-06-13	2025-09-02	Gilead Sciences, Inc.	FXR MODULATING COMPOUNDS (NR1H4)
ES2921432T3 (es)	2016-06-13	2022-08-25	Gilead Sciences Inc	Derivados de azetidina como moduladores de FXR (NR1H4)
IT201600068742A1 (it) *	2016-07-01	2018-01-01	Bar Pharmaceuticals Soc A Responsabilita Limitata	Derivati dell'acido iodesossicolico e loro uso
US10584145B2 (en)	2016-11-29	2020-03-10	Enanta Pharmaceuticals, Inc.	Process for preparation of sulfonylurea bile acid derivatives
WO2018152171A1 (en)	2017-02-14	2018-08-23	Enanta Pharmaceuticals, Inc.	Bile acid derivatives as fxr agonists and methods of use thereof
EP4424364B1 (en)	2017-03-28	2026-01-21	Gilead Sciences, Inc.	Combinations for use in the treatment of cirrhosis and liver fibrosis
ES2971092T3 (es) *	2017-04-07	2024-06-03	Enanta Pharm Inc	Procedimiento para la preparación de derivados de ácidos biliares de carbamato de sulfonilo
CN109021056B (zh) *	2017-06-09	2021-03-09	博瑞生物医药（苏州）股份有限公司	法尼酯x受体激动剂
CN109021054B (zh) *	2017-06-09	2021-04-09	博瑞生物医药（苏州）股份有限公司	一种fxr激动剂
CN109021055B (zh) *	2017-06-09	2021-04-09	博瑞生物医药（苏州）股份有限公司	Fxr激动剂
CN110869381B (zh) *	2017-07-26	2021-11-19	正大天晴药业集团股份有限公司	甾体类衍生物fxr激动剂的制备方法
WO2019085963A1 (zh) *	2017-11-02	2019-05-09	正大天晴药业集团股份有限公司	一种胆酸类化合物的制备方法
PE20211907A1 (es)	2019-01-15	2021-09-28	Gilead Sciences Inc	Compuestos moduladores de fxr (nr1h4)
KR102725082B1 (ko)	2019-02-19	2024-11-04	길리애드 사이언시즈, 인코포레이티드	Fxr 효능제의 고체 형태
JP2022552655A (ja)	2019-10-07	2022-12-19	キャリーオペ，インク．	Ｇｐｒ１１９アゴニスト
CN112824425B (zh) *	2019-11-21	2023-10-03	成都西岭源药业有限公司	一种6-位烯基取代胆酸化合物及其制备方法和应用
PH12022552277A1 (en)	2020-02-28	2024-03-04	Kallyope Inc	Gpr40 agonists
IT202000008515A1 (it)	2020-04-21	2021-10-21	Bar Pharmaceuticals Soc A Responsabilita Limitata	Metodo per la sintesi di un derivato del colano
JP2023526625A (ja)	2020-05-19	2023-06-22	キャリーオペ，インク．	Ａｍｐｋアクチベーター
CN116390925A (zh)	2020-06-26	2023-07-04	卡尔优普公司	Ampk活化剂
EP4433475A4 (en) *	2021-11-15	2026-01-14	Hepaitech Beijing Biopharma Tech Co Ltd	POLYCYCLIC COMPOUNDS AND THEIR PROCESSES
IT202200011705A1 (it) *	2022-06-01	2023-12-01	Prec Bio Therapeutics S R L	Derivati del colesterolo e loro usi
US20250375459A1 (en) *	2022-07-01	2025-12-11	Intercept Pharmaceuticals, Inc.	Methods for ameliorating cognitive impairment using bile acid derivatives
IT202200018669A1 (it)	2022-09-13	2024-03-13	Bar Pharmaceuticals Soc A Responsabilita Limitata	Combinazioni farmaceutiche comprendenti derivati del colano e loro usi
WO2024097247A1 (en) *	2022-10-31	2024-05-10	Intercept Pharmaceuticals, Inc.	Uses of farnesoid x receptor agonists
WO2024195903A1 (ko) *	2023-03-21	2024-09-26	경희대학교 산학협력단	신규한 콜린산 유도체 및 이의 용도
GB202314563D0 (en) *	2023-09-22	2023-11-08	Nzp Uk Ltd	Compounds
WO2025202883A1 (en) *	2024-03-25	2025-10-02	Bar Pharmaceuticals Societa' A Responsabilita' Limitata	Cholane derivatives for the treatment and the prevention of fxr and tgr5gp-bar1 receptors mediated diseases

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002532729A (ja) *	1998-12-23	2002-10-02	グラクソグループリミテッド	核内受容体のリガンドのアッセイ
EP1392714B1 (en) *	2001-03-12	2005-08-31	Intercept Pharmaceuticals, Inc.	Steroids as agonists for fxr
EP1568706A1 (en) *	2004-02-26	2005-08-31	Intercept Pharmaceuticals, Inc.	Novel steroid agonist for FXR
US9498484B2 (en) *	2004-03-12	2016-11-22	Intercept Pharmaceuticals, Inc.	Treatment of fibrosis using FXR ligands
ITMI20050912A1 (it) *	2005-05-19	2006-11-20	Erregierre Spa	Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
DK2040713T3 (da) *	2006-06-27	2014-09-29	Intercept Pharmaceuticals Inc	Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande
US8940719B2 (en) *	2006-07-03	2015-01-27	Academia Sinica	Lithocholic acid analogues that inhibit sialyltransferase
FR2908310B1 (fr) *	2006-11-14	2009-07-10	Phytodia	Produits agonistes de tgr5 et leurs applications
WO2008091540A2 (en) *	2007-01-19	2008-07-31	Intercept Pharmaceuticals, Inc.	23-substituted bile acids as tgr5 modulators and methods of use thereof
EP1947108A1 (en) *	2007-01-19	2008-07-23	Intercept Pharmaceuticals, Inc.	TGR5 modulators and methods of use thereof
AU2009276507B2 (en) *	2008-07-30	2015-11-19	Intercept Pharmaceuticals, Inc.	TGR5 modulators and methods of use thereof
EP2373673B1 (en) *	2008-11-19	2016-07-27	Intercept Pharmaceuticals, Inc.	Tgr5 modulators and methods of use thereof
SG10201400162QA (en) *	2008-11-19	2014-05-29	Intercept Pharmaceuticals Inc	Tgr5 modulators and methods of use thereof
EP4137137A1 (en) *	2010-05-26	2023-02-22	Satiogen Pharmaceuticals, Inc.	Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
WO2012047495A2 (en) *	2010-09-27	2012-04-12	Kythera Biopharmaceuticals, Inc.	Methods for preparing synthetic bile acids and compositions comprising the same
CA2842707A1 (en) *	2011-08-04	2013-02-07	Lumena Pharmaceuticals, Inc.	Bile acid recycling inhibitors for treatment of pancreatitis
SG10201607230SA (en)	2012-06-19	2016-10-28	Intercept Pharmaceuticals Inc	Preparation, Uses And Solid Forms Of Obeticholic Acid
BR112015009395A2 (pt) *	2012-10-26	2017-07-04	Intercept Pharmaceuticals Inc	processo para preparação de derivados do ácido biliar
US20140206657A1 (en) *	2013-01-18	2014-07-24	City Of Hope	Bile acid analog tgr5 agonists
CN103143021A (zh) *	2013-03-21	2013-06-12	中国药科大学	PPARα-UGT通路抑制剂在治疗炎性肠疾病中的应用
DK2997035T3 (en) *	2013-05-14	2018-07-02	Intercept Pharmaceuticals Inc	11-HYDROXY-6-SUBSTITUTED BALIC ACID DERIVATIVES AND AMINO ACID CONJUGATES THEREOF AS FARNESOID X RECEPTOR MODULATORS
WO2015017813A2 (en) *	2013-08-01	2015-02-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Inhibitors of the farnesoid x receptor and uses in medicine
WO2015183794A1 (en) *	2014-05-27	2015-12-03	City Of Hope	Tgr5 agonist complexes for treating diabetes and cancer
WO2015181275A1 (en)	2014-05-29	2015-12-03	Bar Pharmaceuticals S.R.L.	Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases
US20170233431A1 (en) *	2016-02-17	2017-08-17	City Of Hope	Bile acid derivatives and methods for synthesis and use

2015
- 2015-05-28 WO PCT/EP2015/061802 patent/WO2015181275A1/en not_active Ceased
- 2015-05-28 PL PL15731260T patent/PL3149019T3/pl unknown
- 2015-05-28 EP EP19204247.1A patent/EP3626725B1/en active Active
- 2015-05-28 US US15/314,771 patent/US10407462B2/en active Active
- 2015-05-28 MX MX2016015724A patent/MX373721B/es active IP Right Grant
- 2015-05-28 EP EP15731260.4A patent/EP3149019B1/en active Active
- 2015-05-28 SI SI201531924T patent/SI3626725T1/sl unknown
- 2015-05-28 SG SG11201609403UA patent/SG11201609403UA/en unknown
- 2015-05-28 HR HRP20200225TT patent/HRP20200225T1/hr unknown
- 2015-05-28 LT LTEP19204247.1T patent/LT3626725T/lt unknown
- 2015-05-28 FI FIEP19204247.1T patent/FI3626725T3/fi active
- 2015-05-28 ES ES15731260T patent/ES2768718T3/es active Active
- 2015-05-28 CN CN201580028528.2A patent/CN106661079B/zh active Active
- 2015-05-28 CA CA2948585A patent/CA2948585C/en active Active
- 2015-05-28 MX MX2020004024A patent/MX388957B/es unknown
- 2015-05-28 HU HUE19204247A patent/HUE061506T2/hu unknown
- 2015-05-28 PL PL19204247.1T patent/PL3626725T3/pl unknown
- 2015-05-28 KR KR1020167034084A patent/KR102491556B1/ko active Active
- 2015-05-28 JP JP2017514960A patent/JP6820253B2/ja active Active
- 2015-05-28 MA MA39881A patent/MA39881B1/fr unknown
- 2015-05-28 PT PT192042471T patent/PT3626725T/pt unknown
- 2015-05-28 HU HUE15731260A patent/HUE048351T2/hu unknown
- 2015-05-28 HR HRP20230170TT patent/HRP20230170T1/hr unknown
- 2015-05-28 EA EA201692316A patent/EA032820B1/ru unknown
- 2015-05-28 SM SM20230057T patent/SMT202300057T1/it unknown
- 2015-05-28 CN CN201910107511.6A patent/CN110003301B/zh active Active
- 2015-05-28 ES ES19204247T patent/ES2938874T3/es active Active
- 2015-05-28 AU AU2015265893A patent/AU2015265893B2/en active Active
- 2015-05-28 DK DK15731260.4T patent/DK3149019T3/da active
- 2015-05-28 SI SI201531091T patent/SI3149019T1/sl unknown
- 2015-05-28 SG SG10201809362RA patent/SG10201809362RA/en unknown
- 2015-05-28 RS RS20230132A patent/RS64050B1/sr unknown
- 2015-05-28 PT PT157312604T patent/PT3149019T/pt unknown
- 2015-05-28 LT LTEP15731260.4T patent/LT3149019T/lt unknown
- 2015-05-28 SM SM20200070T patent/SMT202000070T1/it unknown
- 2015-05-28 RS RS20200163A patent/RS59910B1/sr unknown
- 2015-05-28 DK DK19204247.1T patent/DK3626725T3/da active
2016
- 2016-11-22 PH PH12016502327A patent/PH12016502327A1/en unknown
2019
- 2019-08-01 US US16/529,571 patent/US11117926B2/en active Active
2020
- 2020-02-12 CY CY20201100131T patent/CY1122631T1/el unknown

Also Published As

Publication number	Publication date
SG10201809362RA (en)	2018-11-29
EP3149019B1 (en)	2019-12-04
AU2015265893A1 (en)	2016-12-08
RS59910B1 (sr)	2020-03-31
US10407462B2 (en)	2019-09-10
EP3626725A1 (en)	2020-03-25
MX2016015724A (es)	2017-07-11
DK3626725T3 (da)	2023-02-27
ES2768718T3 (es)	2020-06-23
PT3626725T (pt)	2023-02-23
EA201692316A1 (ru)	2017-03-31
MX2020004024A (es)	2021-12-10
EP3626725B1 (en)	2022-11-30
SI3149019T1 (sl)	2020-03-31
SMT202000070T1 (it)	2020-03-13
US11117926B2 (en)	2021-09-14
SG11201609403UA (en)	2016-12-29
HRP20200225T1 (hr)	2020-05-29
DK3149019T3 (da)	2020-02-17
KR20170008767A (ko)	2017-01-24
RS64050B1 (sr)	2023-04-28
FI3626725T3 (fi)	2023-03-16
HRP20230170T1 (hr)	2023-03-31
MX373721B (es)	2020-04-20
LT3626725T (lt)	2023-03-10
US20190352328A1 (en)	2019-11-21
WO2015181275A1 (en)	2015-12-03
CY1122631T1 (el)	2021-03-12
CN110003301B (zh)	2022-06-10
CN106661079B (zh)	2019-03-01
AU2015265893B2 (en)	2020-11-12
KR102491556B1 (ko)	2023-01-25
EP3149019A1 (en)	2017-04-05
MA39881B1 (fr)	2020-02-28
JP6820253B2 (ja)	2021-01-27
CA2948585A1 (en)	2015-12-03
SMT202300057T1 (it)	2023-03-17
JP2017516856A (ja)	2017-06-22
ES2938874T3 (es)	2023-04-17
EA032820B1 (ru)	2019-07-31
CN106661079A (zh)	2017-05-10
PL3626725T3 (pl)	2023-04-03
US20170190731A1 (en)	2017-07-06
PH12016502327A1 (en)	2017-02-06
SI3626725T1 (sl)	2023-04-28
PT3149019T (pt)	2020-02-19
PL3149019T3 (pl)	2020-07-27
BR112016028085A2 (pt)	2017-08-22
HUE048351T2 (hu)	2020-07-28
CN110003301A (zh)	2019-07-12
HUE061506T2 (hu)	2023-07-28
WO2015181275A8 (en)	2016-02-18
CA2948585C (en)	2022-07-26
MX388957B (es)	2025-03-20

Publication	Publication Date	Title
SG11201609403UA (en)	2016-12-29	Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases
ZA201908293B (en)	2021-04-28	Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
IL252596A0 (en)	2017-07-31	History of azabicyclooctane as fxr agonists for use in the treatment of liver and gastrointestinal diseases
SG11201607705XA (en)	2016-10-28	Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
IL250663A0 (en)	2017-04-30	Gamma-diketones for the treatment and prevention of skin aging and wrinkles
IL248326A0 (en)	2016-11-30	A dimer of buprenorphine and its use in the treatment of diseases of the stomach and intestines
IL250484A0 (en)	2017-03-30	Heterovesicular compounds and their use in the treatment of tuberculosis
SMT202400084T1 (it)	2024-03-13	Composizione per la prevenzione e/o il trattamento dei sintomi dell’allergia
IL251135A (en)	2017-12-31	A method for the synthesis of hydroxy-triglycerides and their use for disease prevention and treatment
IL248381A0 (en)	2016-11-30	A combination of brexpiprazole and nalemapine and its use in the treatment of drug-related disorders
PT3191112T (pt)	2019-06-27	Compostos de dipeptidilcetoamida e sua utilização para o tratamento e/ou prevenção da acumulação de gordura
EP3223828A4 (en)	2018-06-27	Methods for the treatment and prevention of asbestos-related diseases
AU2014904751A0 (en)	2014-12-11	Methods for the treatment and prevention of asbestos-related diseases
AP2016009662A0 (en)	2016-12-31	Combination of taurine and racemethionine for treatment of liver diseases
GB201415876D0 (en)	2014-10-22	Methods for the treatment and prevention of Ebola